Monoklonale Antikörper gegen das Spike-Protein des SARS-CoV-2-Virus Casirivimab/Imdevimab, Regdanvimab, Sotrovimab und Tixagevimab/Cilgavimab

The monoclonal antibodies casirivimab/imdevimab, regdanvimab, sotrovimab and tixagevimab/cilgavimab are approved in the European Union for the treatment of SARS-CoV-2 infection. They target the spike protein of SARS-CoV-2 and are administered prophylactically after infection in patients at increased risk of severe disease progression. Their approvals are based on randomized controlled trials, in which the drugs could lower the risk for the primary endpoint hospitalization and death. The relative risk reductions were as follows: casirivimab/imdevimab 72,5 % (p < 0,0001);regdanvimab 72,1 % (p < 0,0001);sotrovimab 79,0 % (p < 0,0001).